Loading…
LNSR
LENSAR, Inc.
NASDAQ· Healthcare· Medical Devices· CUSIP 52634L108
$8.30-1.89%Price as of Aug 29, 18:34 UTC · updated once a day, after the close
Key metrics
- Market cap
- $101.97M
- P/E
- 41.5x
- Forward P/E
- —
- P/B
- 6.8x
- Dividend yield
- —
- Payout
- —
- EPS
- $0.20
- ROE
- 357.30%
- Profit margin
- 57.57%
- Revenue growth
- +18.40%
- Beta
- 0.88
- 52-week high
- $12.94
- 52-week low
- $4.95
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -3.2% over 5Y.
today you would have $904.58▼ -9.5%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 6 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Year-end price | $11.63 | $8.94 | $3.51 | $2.96 | $5.99 | $7.25 | |
| P/S | 1.9x | 2.4x | 2.0x | 0.9x | 0.9x | 1.9x | 3.0x |
| P/B | 1.2x | — | 21.7x | 1.2x | 0.8x | 1.2x | 1.2x |
| EPS | -$2.87 |
Fair price, seven ways
Seven formulas applied to what the company reported. None of them predicts a price — each answers what the stock would be worth if its assumption held. The assumption is printed next to every number, because it is the assumption that produces the result.
Earnings
$2.34
Square root of 22.5 × earnings × book value — the two ceilings Graham proposed. Blind to intangibles, so it undervalues software and brands.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
$4.49
Median P/E of 22.4 among peers in the sector.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Operating
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| PLYXPolaryx Therapeutics, Inc. | $2.06 | — | 9.4x | — | -96.56% | $102.68M |
| PYPDPolyPid Ltd. | $5.07 | — | 19.1x | — | -243.59% | $102.98M |
| CRDFCardiff Oncology, Inc. | $1.33 | — | 3.4x | — | -94.08% | $103.47M |
| SEERSeer, Inc. | $1.80 |
About the company
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
- 150
- Orlando, United States
Company description provided by Yahoo Finance.